Google
XLO — XILIO DEVELOPMENT INC (Healthcare >> Biotechnology)
XLO FAQ
What is XLO's P/E ratio?
XILIO DEVELOPMENT INC (XLO) currently trades at a P/E ratio of 5.06.
What is XLO's ROE?
XILIO DEVELOPMENT INC reports a Return on Equity (ROE) of -43.15%.
What is XLO's dividend yield?
XILIO DEVELOPMENT INC offers a dividend yield of 0.00%.
What is XLO's Deepscope Quality Score?
Deepscope rates XLO's overall financial quality at 46 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy XLO?
Deepscope's AI Timing Score for XLO is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does XLO belong to?
XILIO DEVELOPMENT INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 7.70
Price
-0.61
(-7.34%)
Day Change
|
|
|---|
XLO Chất lượng tổng thể của cố phiếu Không tốt ( Chất lượng = 46) và Thời điểm mua ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
Tỷ lệ ROE tương đối thấp
Tỷ lệ ROA tương đối thấp
Lịch sử ROE tương đối thấp
Tốc độ tăng trưởng ROA dưới mức tiêu chí của chúng tôi.
Biên lợi nhuận ròng tương đối thấp.
Tốc độ tăng trưởng biên lợi nhuận ròng dưới mức tiêu chí của chúng tôi
Lịch sử Biên lợi nhuận ròng tương đối thấp.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt lắm , Sức khỏe tài chính Không tốt lắm , và khả năng kiếm lợi nhuận Không tốt lắm , ...
| Yếu tố Chất lượng |
|
51% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 7.70 |
| PBV / Sector |
0.72 / 4.63
GREAT
|
| Earning Per Share | -4.60 |
| PE / Sector |
5.06 / 17.43
GREAT
|
| PEG or PE/Growth / Sector |
0.02 / 0.53
GREAT
|
| Average 1M Daily Value |
0.53 M
GREAT
|
| Average 1W Daily Value |
0.18 M
GREAT
|
| Yếu tố Kỹ thuật |
|
14% |
| Sức khỏe tài chính |
|
50% |
| Khả năng kiếm lợi nhuận |
|
52% |
| Lợi tức cho nhà đầu tư |
|
4% |
| Chi tiết đăng ký |
| Analyze Date | 2026-06-06 09:09:19 |
| Symbol | XLO |
| Name | XILIO DEVELOPMENT INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 6.58 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 52.44 / 8,857.28 |
| Tin tức, Dự báo ước tính |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 828 Winter Street, Waltham, MA, United States, 02451
Phone: 857 524 2466
Website: https://xiliotx.com
Employees: 76
Sector: Healthcare >> Biotechnology
Description: Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
